In this section of our website, you will be able to find links to key documents including patient information leaflets.

Archived documents

• 4. Clinical Preceptor Program
• 13. Review of Cardiac Rehabilitation Provision in Cheshire & Merseyside 2014
• 17. Planned DCCV in Clinic as Elective Out-Patient with Atrial Fibrillation/Flutter
• 29. Updated SOP – Cheshire and Mersey Medicine optimisation of DOACs and review to change agent

Reviewed/Current documentation

• • 1. Guidelines for the Administration of IV and Subcutaneous diuretics for HF Patients in the Ambulatory Setting 2025
  • 2. Pathway to improve access to emergency angiography for comatose patients following cardiac arrest due to myocardial infarction in Cheshire and Merseyside
  • 3. Primary Percutaneous Coronary Intervention (PPCI) Protocol
  • 6. Patient information leaflet Apixaban V2.0 March 2023
  • 7. Patient information leaflet Dabigatran V2.0 March 2023
  • 8. Patient information leaflet Edoxaban V2.0 March 2023
  • 9. Patient information leaflet Rivaroxaban V2.0 March 2023
  • 11. Clinical pathway or people with atrial fibrillation or at risk of atrial fibrillation
  • 12. Cheshire and Merseyside Heart Failure Competency record
  • 14. Sacubitril/Valsartan (Entresto®) treatment algorithm
  • 15. Statement on the use of Sacubitril/Valsartan (Entresto ®) for the treatment of symptomatic chronic heart failure with reduced ejection fraction
  • 16. GP Communication Letter Sacubitril/Valsartan (Entresto ®)
  • 22. Statement on the use of Sacubitril/Valsartan (Entresto ®) for the treatment of symptomatic chronic heart failure with reduced ejection fraction
  • 23. Decision Aid – New initiation of DOACs in AF April 2025
  • 27. Cheshire and Merseyside FAQ – Meds Optimisation of DOACs in AF April 2025
  • 30. BP Opportunistic Testing Guideline V2.3
  • 32. Lifespan Pathway for Lipids 2024
  • 33. DOAC Statement Cheshire and Merseyside April 2025
  • 35. Guide for patients to understand changes in anticoagulation (DOACs) V2